...
首页> 外文期刊>British journal of nursing: BJN >Current clinical overview of cutaneious melanoma.
【24h】

Current clinical overview of cutaneious melanoma.

机译:皮肤黑素瘤的当前临床概述。

获取原文
获取原文并翻译 | 示例

摘要

This article reviews current evidence on epidemiology, diagnosis and management of cutaneous melanoma. Incidence of cutaneous melanoma is rising in all Caucasian populations across the world; thus, melanoma represents a significant public health burden. Although, incidence of melanoma is in continuous increase, a decrease of mortality and improved survival has been observed in most western European populations. Clinical characteristics of four major types of melanoma (superficial spreading, nodular, lentigo maligna melanoma and acral lentiginous melanoma) have been described. Surgical removal of melanoma remains the standard care in all primary melanomas. Current evidence suggests use of 1 to 2 cm excision margins. Wider margins may be necessary in patients with thicker melanomas with higher risk for local recurrence. In the treatment of regional lymph nodes elective lymphadenectomy has been surpassed by the sentinel lymph node biopsy (SLNB). However, although prognostic value of SLNB has been confirmed, its therapeutical benefit still needs to be evaluated. Currently there is no standard adjuvant therapy for melanoma although interferon-alpha has been the most widely used treatment in the adjuvant setting. The role of metastasectomy (removal of distant metastases) is still controversial. Chemotherapeutic agents have a limited activity in patients with metastatic melanoma with response rates up to 25%. Although different vaccines have been tested in melanoma patients their role still remain to be established in phase III trials. Progresses in molecular biology and genetics of melanoma may lead to the development of novel melanoma therapies.
机译:本文回顾了有关皮肤黑素瘤的流行病学,诊断和管理的最新证据。全世界所有白种人中,皮肤黑色素瘤的发病率正在上升。因此,黑色素瘤代表了巨大的公共卫生负担。虽然,黑色素瘤的发病率不断增加,但在大多数西欧人口中已观察到死亡率降低和存活率提高。已经描述了四种主要类型的黑色素瘤的临床特征(浅表性扩散,结节状,恶性扁桃状黑色素瘤和急性肢端黑色素性黑色素瘤)。手术切除黑色素瘤仍是所有原发性黑色素瘤的标准治疗方法。当前证据表明使用1到2 cm的切缘。黑色素瘤较厚,局部复发风险较高的患者可能需要更大的切缘。在局部淋巴结的治疗中,前哨淋巴结活检(SLNB)已超越了选择性淋巴结清扫术。然而,尽管已经证实了SLNB的预后价值,但仍需要评估其治疗益处。尽管干扰素-α是辅助治疗中使用最广泛的治疗方法,但目前尚无用于黑色素瘤的标准辅助治疗方法。转移瘤切除术(远处转移瘤切除术)的作用仍存在争议。化学治疗剂对转移性黑色素瘤患者的活性有限,应答率高达25%。尽管已经在黑色素瘤患者中测试了不同的疫苗,但其作用仍需要在III期试验中确立。黑色素瘤的分子生物学和遗传学研究进展可能导致新型黑色素瘤疗法的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号